Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Rating) major shareholder Ra Capital Management, L.P. purchased 824,600 shares of the company's stock in a transaction that occurred on Wednesday, December 14th. The stock was purchased at an average price of $5.46 per share, for a total transaction of $4,502,316.00. Following the purchase, the insider now owns 7,824,600 shares in the company, valued at $42,722,316. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Large shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.
Ra Capital Management, L.P. also recently made the following trade(s):
Get
Fulcrum Therapeutics alerts:
- On Friday, December 16th, Ra Capital Management, L.P. bought 1,341,420 shares of Fulcrum Therapeutics stock. The stock was purchased at an average cost of $5.42 per share, with a total value of $7,270,496.40.
Fulcrum Therapeutics Price Performance
Shares of FULC stock opened at $5.35 on Friday. Fulcrum Therapeutics, Inc. has a 1 year low of $3.21 and a 1 year high of $24.79. The firm has a fifty day moving average price of $6.37 and a 200-day moving average price of $6.69. The company has a market cap of $278.47 million, a price-to-earnings ratio of -2.09 and a beta of 1.96.
Analyst Upgrades and Downgrades
Several brokerages recently weighed in on FULC. The Goldman Sachs Group assumed coverage on shares of Fulcrum Therapeutics in a research report on Tuesday, November 15th. They set a "buy" rating and a $11.00 price target for the company. Credit Suisse Group reduced their target price on Fulcrum Therapeutics from $22.00 to $19.00 and set an "outperform" rating for the company in a report on Wednesday, November 9th. Morgan Stanley upped their price target on Fulcrum Therapeutics from $25.00 to $26.00 and gave the company an "overweight" rating in a report on Monday, November 14th. Oppenheimer reduced their price objective on Fulcrum Therapeutics to $30.00 in a report on Tuesday, November 15th. Finally, Stifel Nicolaus decreased their target price on Fulcrum Therapeutics from $43.00 to $35.00 in a research report on Thursday, October 20th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $22.71.
Institutional Trading of Fulcrum Therapeutics
Several hedge funds have recently bought and sold shares of the stock. Sandia Investment Management LP purchased a new position in shares of Fulcrum Therapeutics during the 3rd quarter valued at about $40,000. Delphia USA Inc. purchased a new position in Fulcrum Therapeutics during the second quarter valued at approximately $58,000. SG Americas Securities LLC boosted its position in shares of Fulcrum Therapeutics by 207.1% in the second quarter. SG Americas Securities LLC now owns 13,173 shares of the company's stock worth $65,000 after purchasing an additional 8,884 shares during the period. AQR Capital Management LLC bought a new position in shares of Fulcrum Therapeutics in the second quarter worth approximately $68,000. Finally, Allspring Global Investments Holdings LLC purchased a new stake in shares of Fulcrum Therapeutics in the third quarter worth $74,000. Institutional investors own 96.96% of the company's stock.
About Fulcrum Therapeutics
(Get Rating)
Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Further Reading
- Get a free copy of the StockNews.com research report on Fulcrum Therapeutics (FULC)
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
